News & Updates

Show Multimedia Only
A roundtable on cochlear implantation
A roundtable on cochlear implantation
16 Apr 2025 byPank Jit Sin

A panel of experts in the field of hearing and cochlear implantation congregated to provide some insight into the topic. The panel consisted of Yuzaida Md Yusoff, senior audiologist, Department of Otorhinolaryngology, Hospital Sultanah Bahiyah, Kedah; Associate Professor Dr Noor Dina Hashim, Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Hospital Canselor Tuanku Muhriz UKM; Wan Fazlina Wan Hashim, head of Audiology Unit, Hospital Canselor Tuanku Muhriz UKM; Professor Emeritus Dato’ Dr Lokman Saim, President of College of Otorhinolaryngologists-Head and Neck Surgeons (CORLAMM), Vice Chancellor and ORL-HNS Senior Consultant KPJ Healthcare University, Negeri Sembilan; and Professor Dr Goh Bee See, Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Hospital Canselor Tuanku Muhriz UKM. A panel of experts in the field of hearing and cochlear implantation congregated to provide some insight into the topic. The panel consisted of Yuzaida Md Yusoff, senior audiologist, Department of Otorhinolaryngology, Hospital Sultanah Bahiyah, Kedah; Associate Professor Dr Noor Dina Hashim, Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Hospital Canselor Tuanku Muhriz UKM; Wan Fazlina Wan Hashim, head of Audiology Unit, Hospital Canselor Tuanku Muhriz UKM; Professor Emeritus Dato’ Dr Lokman Saim, President of College of Otorhinolaryngologists-Head and Neck Surgeons (CORLAMM), Vice Chancellor and ORL-HNS Senior Consultant KPJ Healthcare University, Negeri Sembilan; and Professor Dr Goh Bee See, Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Hospital Canselor Tuanku Muhriz UKM.

A roundtable on cochlear implantation
16 Apr 2025
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025 byStephen Padilla

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025